Investigating the effectiveness of Alsava drug on the average NIHSS score in patients with acute ischemic stroke

Investigating the effectiveness of Alsava drug on the average NIHSS score in patients with acute ischemic stroke in Shahid Sadoughi Hospital in Yazd in 2024

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190425043368N3

Enrollment

Registered

2025-12-10

Start date

2025-12-13

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke. Cerebrovascular disorders in diseases classified elsewhere

Interventions

Intervention group: The group receiving edaravone (brand name Alsava).

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Definitive diagnosis of acute ischemic stroke based on clinical and imaging findings Onset of symptoms less than 4.5 hours Age older than 18 years NIHSS score two to twenty-five (2 to 25)

Exclusion criteria

Exclusion criteria: Hemorrhagic stroke or bleeding on a brain CT scan Severe renal and hepatic failure Presence of severe and unstable underlying diseases Contraindications for the use of Alsava (Edaravone)

Design outcomes

Primary

Measure	Time frame
Mean nihss score. Timepoint: Average NIHSS score at admission, at discharge, and two months after treatment. Method of measurement: The National Institutes of Health Stroke Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahtabalsadat Mirjalili

Yazd University of Medical Sciences

Mahtab.mirjalili@gmail.com+98 35 3820 3419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026